NCT05672537 2023-01-05
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
Tianjin Medical University Cancer Institute and Hospital
Delcath Systems Inc.
Sun Yat-sen University
Zhejiang University